What is the recommended treatment for uncomplicated Plasmodium vivax malaria, including dosing, management of chloroquine resistance, G6PD deficiency, and considerations in pregnancy?

Treatment of Plasmodium vivax Malaria

For uncomplicated P. vivax malaria, chloroquine (1000 mg salt initially, then 500 mg at 6,24, and 48 hours) remains first-line treatment in chloroquine-sensitive areas, followed by primaquine 30 mg base daily for 14 days for radical cure after confirming G6PD sufficiency. 1

Blood-Stage Treatment Algorithm

Chloroquine-Sensitive P. vivax (Most Areas)

First-line: Chloroquine is the preferred treatment 1:

• Dosing: 4 tablets (1000 mg salt) initially, then 2 tablets (500 mg salt) at 6,24, and 48 hours
• Alternative formulations: Chloroquine sulphate (600 mg base, then 300 mg base at same intervals) or hydroxychloroquine (800 mg salt, then 400 mg salt)
• Adverse effects: Nausea, vomiting, pruritus, postural hypotension 1

Chloroquine-Resistant P. vivax (Papua New Guinea, Indonesia)

Use artemisinin-based combinations 1:

• Preferred: Dihydroartemisinin-piperaquine (DHA-PPQ) - favored due to longer piperaquine half-life 1
• Alternatives: Artemether-lumefantrine (AL), atovaquone-proguanil, or mefloquine
• These are the same regimens used for P. falciparum

A 2019 trial demonstrated chloroquine and DHA-PPQ had equivalent efficacy when combined with high-dose primaquine, with no difference in recurrence rates 2.

Radical Cure (Hypnozoite Elimination)

Critical principle: Blood-stage treatment alone does NOT prevent relapses - an 8-aminoquinoline is mandatory 3.

G6PD Testing Requirements

Test BEFORE prescribing primaquine or tafenoquine 1:

• Quantitative testing preferred for females (can detect heterozygotes with intermediate deficiency) 4
• Point-of-care quantitative G6PD testing has proven operationally feasible with 100% appropriate drug use 4
• Do not use qualitative tests alone in females - they miss intermediate deficiency 5

Primaquine Regimens Based on G6PD Status

G6PD Normal (≥70% activity):

• Standard dose: 30 mg base daily for 14 days 1
• High-dose alternative: 0.5 mg/kg/day for 14 days OR 1 mg/kg/day for 7 days (both total 7 mg/kg) - equally effective 2
• The 7-day regimen showed identical radical cure efficacy to 14-day treatment (12% recurrence rate for both) 2

G6PD Intermediate Deficiency (30-70% activity, African A- variant):

• Weekly primaquine: 0.75 mg base/kg (maximum 45 mg) weekly for 8 weeks 1
• Close monitoring required for hemolysis
• Do NOT use this regimen for Mediterranean (B-) variant - very high hemolysis risk 1

G6PD Deficient (<30% activity):

• No primaquine - use chloroquine suppression during pregnancy or high-risk periods
• Consider tafenoquine contraindicated

Tafenoquine Alternative

Single 300 mg dose (two 150 mg tablets) 1:

• Requires quantitative G6PD ≥70% 1
• FDA restricts coadministration with chloroquine only 1
• Not available in Europe; approved in US and Australia only 1
• Limited evidence for delayed administration (>3 days after chloroquine), though likely superior to chloroquine alone 6

Monitoring for Hemolysis

Common pitfall: Primaquine-induced hemolysis can occur even with negative qualitative G6PD tests in heterozygous females 7.

Watch for:

• Dark urine (hemoglobinuria)
• Fatigue, pallor, dyspnea
• Hemoglobin drop >2 g/dL or below 7 g/dL

In a 2025 Ethiopian study with low G6PD deficiency prevalence, low-dose primaquine (0.25 mg/kg) showed median hemoglobin drop of only 0.9% on day 3, with 91.9% hematological recovery by day 13 8. However, an Afghanistan trial reported 5 possible hemolysis cases requiring hospitalization, though none met severe criteria 9.

Special Populations

Pregnancy

Blood-stage treatment:

• Chloroquine is safe in all trimesters 1, 3
• Hydroxychloroquine preferred for prolonged suppression due to better tolerability 5
• Quinine plus clindamycin is alternative 1

Radical cure:

• Primaquine and tafenoquine are CONTRAINDICATED - fetal G6PD status unknown 1
• Use chloroquine/hydroxychloroquine suppression throughout pregnancy
• Defer radical cure until after delivery and breastfeeding

Severe/Complicated Malaria (Any Species)

First-line: IV artesunate 2.4 mg/kg at 0,12,24 hours, then daily 1

• Switch to oral ACT when able (parasite density <1%, tolerating oral)
• Monitor for post-artesunate delayed hemolysis (PADH)

Second-line: IV quinine if artesunate unavailable 1

• Loading dose 20 mg salt/kg over 4 hours
• Maintenance 10 mg/kg every 8 hours
• Monitor for QT prolongation and hypoglycemia 3

Key Clinical Pitfalls

1. Forgetting radical cure: Chloroquine alone has 78% therapeutic failure at 28 days vs. 15% with primaquine 10
2. Using qualitative G6PD tests in females: Misses heterozygotes at risk for hemolysis 5
3. Prescribing primaquine in pregnancy: Absolute contraindication 1
4. Inadequate patient counseling: Leads to incorrect dosing and preventable hemolysis 7
5. Assuming chloroquine efficacy everywhere: Resistance widespread in Papua New Guinea and Indonesia 1, 3